A Sensitive and Specific Non-Invasive Urine Biomarker Panel for Prostate Cancer Detection

Prostate cancer remains one of the most commonly diagnosed malignancies in men, and while prostate-specific antigen (PSA) testing has played a central role in early detection, it has clear limitations. It is known that PSA is highly sensitive but not specific, often leading to unnecessary prostate biopsies and exposing patients to avoidable risks. In this context, it is imperative to develop accurate and non-invasive biomarkers that can better distinguish between malignant and benign prostate diseases.

In our recent study, published in EBioMedicine (The Lancet), we validated a three-marker urine panel (TTC3, H4C5, EPCAM) across development and independent validation cohorts involving nearly 900 men. The panel achieved excellent diagnostic accuracy, with an AUC of 0.96 in development and 0.92 in validation, consistently outperforming the widely used PCA3 urine assay. Importantly, biomarker expression diminished after prostatectomy and was confirmed to originate from malignant prostatic tissue, strengthening its biological relevance.

Clinically, this assay offers several advantages. Unlike other urine-based tests, our panel does not require prostate massage or digital rectal examination, making sample collection simpler and less invasive. Patients only need to provide a urine specimen, which can be obtained in any clinical setting. The test also demonstrated high performance in patients with PSA values in the “normal” range, a group often missed by conventional screening. Most importantly, its accuracy in distinguishing prostate cancer from benign prostatic hyperplasia and prostatitis suggests that it can reduce the number of unnecessary biopsies and their potential complications.

These findings represent a significant step forward in prostate cancer diagnostics and management. A sensitive, specific, and non-invasive urine test has the potential to improve early detection, reduce overdiagnosis, and refine patient selection for biopsy and follow-up.

Additional prospective studies and integration into clinical settings are essential, but this work establishes a strong basis for a practical, patient-friendly assay that could meaningfully change prostate cancer detection and management worldwide.

Written by: Marcio Covas Moschovas, MD, PhD, FACS, AdventHealth Global Robotics Institute, Celebration, FL

Read the Abstract

Login